Polysorbate-80 surface modified nano-stearylamine BQCA conjugate for the management of Alzheimer's disease.
Pavan Kumar ChintamaneniPraveen Thaggikuppe KrishnamurthySai Kiran S S PindiproluPublished in: RSC advances (2021)
Acetylcholinesterase (AChE) inhibitors such as donepezil, galantamine and rivastigmine are used for the management of dementia in Alzheimer's Disease (AD). These drugs elevate endogenous acetylcholine (ACh) levels at the M 1 muscarinic receptor in the brain to achieve therapeutic benefits. However, their side effects, such as nausea, vomiting, dizziness, insomnia, loss of appetite, altered heart rate, etc. , are related to non-specific peripheral activation of M 2 -M 5 muscarinic subtypes. It is logical, therefore, to develop drugs that selectively activate brain M 1 receptors. Unfortunately, the orthosteric site homology among the receptor subtypes does not permit this approach. An alternative approach is to use positive allosteric modulator (PAM) of M 1 receptors like benzyl quinolone carboxylic acid (BQCA). PAMs although devoid of M1 agonist activity, however, when bound, enhance the binding affinity of orthosteric ligand, Ach. The current challenge with PAMS is their low brain half-life, permeability, and higher elimination rates. This study reports active targeting of brain M1 receptors using surface modified nano lipid-drug conjugates (LDC) of M1 PAM, BQCA, to treat AD. Polysorbate-80 (P-80) surface modified stearylamine (SA)-BQCA conjugated nanoparticles (BQCA-SA-P80-NPs) were prepared by conjugating BQCA to SA, followed by the formation of nanoparticles (NPs) using P-80 by solvent injection method. The BQCA-SA-P80-NPs are near-spherical with a particle size (PS) of 166.62 ± 1.24 nm and zeta potential (ZP) of 23.59 ± 0.37 mV. In the in vitro cytotoxicity (SH-SY5Y cells) and hemolysis assays, BQCA-SA-P80-NPs, show acceptable safety and compatibility. In mice, Alzheimer's model, BQCA-SA-P80-NPs significantly prevent STZ induced changes in memory, neuronal Aβ 1-42 , p-Tau, APP, NF-κB, and BACE levels and neuronal cell death, when compared to untreated disease control and naïve BQCA treated group. Further, BQCA-SA-P80-NPs significantly improve the therapeutic efficacy of AChE inhibitor, donepezil (DPZ), indicating its potentiating effects. In vivo biodistribution studies in mice show selective accumulation of BQCA-SA-P80-NPs in the brain, suggesting an improved brain bioavailability and reduced peripheral side effects of BQCA. The study results demonstrate that BQCA-SA-P80-NPs can improve brain bioavailability and therapeutic efficacy of BQCA in AD.
Keyphrases
- resting state
- white matter
- heart rate
- cell death
- functional connectivity
- photodynamic therapy
- oxide nanoparticles
- computed tomography
- heart rate variability
- blood pressure
- signaling pathway
- immune response
- type diabetes
- chemotherapy induced
- oxidative stress
- weight loss
- working memory
- cell proliferation
- insulin resistance
- inflammatory response
- depressive symptoms
- cell cycle arrest
- high throughput
- skeletal muscle
- metabolic syndrome
- transcription factor
- fatty acid
- mass spectrometry
- cerebrospinal fluid